Kornimate/medical-research-clean huggingface dataset:
efficacy of lavender essential oil chest wraps in infants with bronchiolitis

Conditions: Bronchiolitis

Summary: the goal of this clinical trial is to learn if lavender essential oil chest wraps relieve cough in infants with bronchiolitis compared to standard care. furthermore, the researchers will evaluate if breathing difficulties, nighttime awakening and impact on parents will be improved by the lavender oil chest wraps. infants will be randomized to receive standard care with the addition of lavender oil chest wraps or to receive standard care alone. the study will take place in two locations in switzerland, at the geneva university hospital and the fribourg cantonal hospital.


Eligibility criteria:
inclusion criteria: * bronchiolitis: clinical diagnosis based on the combination of respiratory distress (tachypnea, grunting, nasal flaring, retractions, and/or need for supplementary oxygen) and fine crackles sometimes accompanied by wheezing on auscultation. * hospitalization. * written informed consent. exclusion criteria: * patients with underlying diseases that impact respiratory or heart function (congenital heart disease, congenital malformation of the lung or airway system and severe chronic lung disease). * more than 3 episodes of bronchiolitis. * critically ill infants who have an immediate need for intensive care unit (icu) admission. * respiratory deterioration needing continuous positive airway pressure (cpap) or transfer to icu during study enrollment. * atopic dermatitis, eczema or other skin lesions (particularly on the chest). * oncologic disease. * premature infants with mild bronchopulmonary dysplasia will not be excluded.

Keywords: bronchiolitis infant cough essential oil lavendula complementary therapies
bacteria and intestinal translocation in surgery (bandit)

Conditions: Surgical Site Infection

Summary: patients undergoing elective abdominal surgery will be included prospectively. informed consent will be obtained. preoperatively baseline health data is collected and a skin swab and rectal swab for baseline skin and gut microbiota is taken. during the surgery additional clinical data and additional samples will be obtained. additional samples include: rectal swab, biopsies of the resected specimen (lymph node, peritoneum, intestinal content, mucosa), venous blood sample (7.5ml) at the end of the operation, liver biopsy and skin biopsy. postoperative health data is recorded. if a surgical site infection occurs a swab is taken too. with 16 srna (small ribonucleic acid) based sequencing the investigators will quantify the abundance of the different bacterial species in all samples. primary outcome will be to assess a difference of 16srna signal in the liver and lymph node biopsies between patients with and patients without surgical site infection. secondary outcomes include variables predicting the occurence of surgical site infections and a model describing the way bacteria may take to cause wound infection.


Eligibility criteria:
inclusion criteria: * informed consent * all ages * all gender * elective abdominal surgery * age \> 18 * all approached (laparoscopic, open) * all ethnic and sociodemographic backgrounds * sufficient knowledge of the study language (german) exclusion criteria: * pregnant or lactating women * no operation performed (i.e. only planned) * insufficient knowledge of project language (german) * lack of informed consent * known colonization with multi-resistant bacteria (e.g. methicillin-resistant staphylococcus aureus (mrsa) or extended spectrum betalactamase (esbl)) * known cirrhotic liver disease
nt0102 in the treatment of children with attention deficit hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)

Summary: this is a randomized, double-blind, placebo-controlled, parallel group, phase 3 trial to evaluate the safety and efficacy of nt0102 in the treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients 6 to 12 years of age in a laboratory classroom study.


Eligibility criteria:
inclusion criteria: * currently being treated for adhd exclusion criteria: * other psychiatric diagnoses * significant cognitive impairment * chronic medical illnesses * structural cardiac defects * significant abnormal lab tests * taking disallowed medications * positive drug test
evaluating the effectiveness of a cognitive behavioral intervention (cbi)

Conditions: Adolescent Behavior; Dental Plaque; Gingivitis; Cognitive Change

Summary: this is a phase iii, randomized, one-center, three arm parallel group, open label and single blind clinical study to evaluate the effectiveness of a cognitive behavioral intervention (cbi) adjunctive to a smart powered toothbrush on the oral health of adolescents.

this is a phase iii, randomized, one-center, three arm parallel group, open label and single blind clinical study to evaluate the effectiveness of a cognitive behavioral intervention (cbi) adjunctive to a smart powered toothbrush on the oral health of adolescents. outcomes briefly summarized include the plaque score, gingival score and a survey of knowledge, attitudes and procedures measured at 1,3 and 6 months participating subjects will be randomized to one of the following products: test group i a commercially available fluoride toothpaste (1450 ppm f) a commercially available smart electric toothbrush control group i a commercially available fluoride toothpaste (1450 ppm f) a commercially available smart electric toothbrush control group ii a commercially available fluoride toothpaste (1450 ppm f) a commercially available soft bristle toothbrush

Eligibility criteria:
inclusion criteria: students are enrolled in participating high schools caregivers give informed consent student gives assent exclusion criteria: * having a prosthetic heart valve * having a history of previously having infective endocarditis * having had joint replacement surgery * children on blood thinner medication such as coumadin or rivaroxaban * children who are currently receiving chemotherapy * children who have received organ transplants of any type * children with leukemia

Keywords: adolescent health dental plaque gingivitis cognitive change
evaluation of a surgical microscope mounted autorefractor when used on patients lying in a supine position

Conditions: Refractive Error

Summary: the purpose of this study is to evaluate the accuracy and repeatability of an individually validated prototype autorefractor designed to be mounted on a surgical microscope.

the purpose of this study is to evaluate the accuracy and repeatability of an individually validated prototype autorefractor designed to be mounted on a surgical microscope. the goal is to evaluate 20 subjects with both the investigational instrument followed by a commercially available instrument.

Eligibility criteria:
inclusion criteria: 1. be at least 18 years of age as of the date of evaluation for the study. 2. have: 1. read the informed consent 2. been given an explanation of the informed consent 3. indicated understanding of the informed consent 4. signed the informed consent document. 3. be willing and able to adhere to the instructions set forth in this protocol and able to participate in all scheduled evaluations. 4. be in good general health, based on his/her knowledge. 5. have a refractive error within the range of -10.00 to +30.00 diopter sphere and up to 5.00 diopter of refractive cylinder . 6. have manifest refraction (bcva) snellen visual acuities (va) equal to or better than 20/25 in each eye. - exclusion criteria: subjects may not be enrolled in this study if any of the following apply: the subject is/has: 1. allergy to tropicamide or a previous adverse reaction to tropicamide. 2. poor personal hygiene as observed by the investigational site personnel. 3. strabismus 4. currently pregnant (to the best of the subject's knowledge) or is lactating. 5. previous refractive surgery or current or previous orthokeratology treatment. 6. aphakic or pseudophakic or has cataracts that interfere with visual acuity. 7. ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type ii diabetes. 8. the need for topical ocular medications or any medication which might interfere with the study evaluations. 9. the presence of clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures. 10. slit lamp findings, including but not limited to: pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> grade 2 pterygium corneal scars within the visual axis neovascularization or ghost vessels \> 1.0 mm in from the limbus giant papillary conjunctivitis (gpc) of \> grade 2 anterior uveitis or iritis seborrheic eczema, seborrheic conjunctivitis or blepharitis -

Keywords: autorefractor
cisplatin plus raltitrexed or 5-fluorouracil concurrent with radiotherapy for head and neck squamous cell cancer

Conditions: Head and Neck Squamous Cell Cancer

Summary: this study is a multicenter phase ⅲ trial. the objective is to compare the efficacy and toxicity of cisplatin plus raltitrexed or 5-fluorouracil in concurrence with imrt for patients with locoregionally advanced head and neck squamous cell cancer.

the objective is to compare the efficacy and toxicity of cisplatin plus raltitrexed or 5-fluorouracil in concurrence with imrt for patients with locoregionally advanced head and neck squamous cell cancer.

Eligibility criteria:
inclusion criteria: * pathologically confirmed untreated head and neck squamous cell cancer patients * 18-70 years * clinical stage: t3-4n0-3m0 or t1-4n1-3m0 * hematologic function: wbc ≥ 4.0×109/l, plt ≥ 80×109/l, hb ≥ 10mg/dl * renal function: cr ≤ 1.25×unl * hepatic function: bil ≤ 1.5×unl, alt/ast ≤ 2.5×unl * ecog ≤ 1 * woman and man of childbearing age must adopt contraception * with written consent exclusion criteria: * malignant history * pregnant or lactating women * with other severe diseases (blood, liver ,kidney or heart diseases) * subjects not suitable for chemo-radiotherapy * without written consent
weight implements to improve throwing speed and shoulder mobility in baseball pitchers

Conditions: Baseball Pitcher

Summary: increasing the speed of pitches is key in baseball performance. the interventions by means of the implement of weights are used to improve the strength and to strengthen the muscles of the shoulder. the objective of the study is to assess the effectiveness of an exercise protocol with weight implements in increasing the speed of throws and shoulder mobility in pitchers aged 18 to 40 years. randomized pilot study. 12 pitchers will be randomized to the study groups: experimental (intervention with launches with weight implement) and control (without any intervention). the intervention will last 4 weeks, with 2 weekly sessions of 15 minutes each. the study variables will be the range of shoulder movement (goniometry) and the speed of the throws (speed radar). a descriptive statistical analysis will be performed calculating median and interquartile range. with the shapiro-wills test, the sample distribution will be calculated. if there is homogeneity, with the t-student test the changes will be calculated after the intervention in both groups. the intra and intersubject effect will be calculated with the anova of repeated measures. the effect size will be obtained with cohen's mean difference formula. it is expected to see improvement in the speed of the throws and in the range of shoulder movement.


Eligibility criteria:
inclusion criteria: * male baseball pitchers * with an age range of 18 to 40 years * with more than three years of sports practice as a pitcher * that currently practice in regional or professional competitions exclusion criteria: * subjects who have undergone some surgery on the dominance arm with which they launch in the last 12 months * who are receiving a specific shoulder mobility intervention * have not signed the informed consent document

Keywords: baseball pitchers weight implements speed of pitches range of motion
split-face study comparing botox and jeuveau in treating glabellar lines

Conditions: Glabellar Frown Lines

Summary: the purpose of this study is to compare the efficacy and side effects of botox and jeuveau for glabellar lines.

after being informed about the study and potential risks, all patients given consent will receive botox on one side of their face and jueveau on the other. a random number generator will generate a list of 20 combinations of "1,2" or "2,1". "1,2" means the botox (onabotulinumtoxin a) will be placed on the right side and "2,1" means that the botox will be placed on the left. the other side will be injected with prabotulinumtoxina. 8-10 units will be injected into the designated glabella in 3 sites.

Eligibility criteria:
inclusion criteria: * age \> 18 * willingness to participate in the study and able to provide informed consent exclusion criteria: * inability to follow up for study duration * prior neurotoxin injection in the last 4 months * prior surgery to the glabellar area * any planned aesthetic procedure to the glabellar area during the study period * cardiac patients

Keywords: botox, jeuveau
local wound infiltration plus tap block versus local wound infiltration only

Conditions: Colorectal Disorders

Summary: the tap block is typically performed either with ultrasound guidance (tap-us) or laparoscopic visualization (tap-lap): comparison between these two technics showed no differences in pain control and use of opioid analgesics. the investigators hypothesize that wi is non-inferior to wi + tap-block with respect to postoperative pain.

in colorectal surgery, laparoscopy and enhanced recovery after surgery (eras) programs have significantly improved the short-term outcomes (1). although the laparoscopic approach reduces pain and recovery time, post-operative pain, nausea and vomiting still represent an issue. in order to reduce opioid related side effects, such as postoperative nausea and vomiting (ponv), constipation and prolonged post-operative ileus, non-opioid based multimodal analgesia have been recently introduced. although epidural analgesia has gained good success, it does not seem to offer any additional clinical benefits to patients undergoing laparoscopic colorectal surgery compared to alternative analgesic technique within an eras program. both local wound infiltration (wi) and tap block are common techniques in multimodal postoperative pain treatment, and their association allows to achieve pain control despite a reduced use of opioid analgesics. furthermore, in a recent single-blind prospective study tap block resulted superior to wound infiltration alone. the tap block is typically performed either with ultrasound guidance (tap-us) or laparoscopic visualization (tap-lap): comparison between these two technics showed no differences in pain control and use of opioid analgesics. the aim of this study is to compare wi + tap-lap versus wi alone. the investigators hypothesize that wi is non-inferior to wi + tap-block with respect to postoperative pain.

Eligibility criteria:
inclusion criteria: * aged 18-80 years, either sex * patients scheduled to undergo elective laparoscopic colorectal surgery under general anesthesia * willingness and ability to sign an informed consent document exclusion criteria: * allergies to anesthetic or analgesic medications * contraindication to the use of locoregional anesthesia * chronic opioid use * coagulopathy, impaired kidney function, uncontrolled diabetes, psychiatric disorders, severe cardiovascular impairment or chronic obstructive lung disease * necessity of major resection other than colorectal, palliative surgery * bmi above 35 kg/m2 * american society of anesthesiologists (asa) physical status above 3
new mammographic techniques versus mri in assessment of breast lesions

Conditions: Breast Diseases

Summary: value of new mammography techniques in comparison to dynamic contrast-enhanced mri of the breast in the detection and diagnosis of breast lesions

combined use of contrast-enhanced digital mammography (cedm), and digital breast tomosynthesis (dbt), may be a reasonable alternative to mri.

Eligibility criteria:
inclusion criteria 1. breast imaging reporting and data system (bi-rads) 3, 4, and 5 breast lesions. 2. clinical indication for mri breast imaging. 3. no histologically proven cancer before enrollment. exclusion criteria 1. pregnancy or possible pregnancy. 2. history of allergy to an iodinated contrast agent. 3. renal impairment. 4. contraindication for mri examination
the impact of anticipatory guidance on early childhood caries: a quasi-experimental study

Conditions: Dental Caries in Children

Summary: this study aimed to compare the impact of anticipatory guidance on the caries incidence of 2-3-year-old preschool children and their 4-6-year-old siblings, as well as on their mothers' oral health literacy, as compared to the conventional ministry of health (moh) programme.

this quasi-experimental study was conducted at two government dental clinics in batu pahat district, malaysia. the samples comprised of 478 mother-child-sibling trios (233 families in the intervention group, and 245 families in the control group). an oral health package named the family dental wellness programme (fdwp) was designed to provide anticipatory guidance to the intervention group at six-month intervals over three years. the control group received the standard moh oral health education activities. the impact of fdwp on net caries increment, caries prevented fraction, and mother's oral health literacy was assessed after three years of intervention.

Eligibility criteria:
inclusion criteria: * children between the age of 2-3 years old * older sibling aged 4 to 6 years categorized as having high caries risk based on a caries risk assessment tool adapted from the american association of paediatric dentistry * mothers who were willing to participate in the study exclusion criteria: • medically compromised children

Keywords: dental caries oral health literacy
global phase1 study to assess the safety and tolerability of azd1208 in advanced solid tumors and malignant lymphoma

Conditions: Advanced Solid Malignancies; Malignant Lymphoma

Summary: the purpose of this study is to investigate the safety and tolerability of azd 1208 up to a maximum tolerated dose (mtd) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid malignancies including malignant lymphoma

a phase i, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of azd1208 in patients with advanced solid malignancies including malignant lymphoma

Eligibility criteria:
inclusion criteria: * patients who have signed this written informed consent form after a full explanation about the participation in this study * patients aged 18 years or older patients diagnosed with a solid malignant tumour or malignant lymphoma that is refractory to standard therapies or for which no standard therapies exist * patients with good physical conditions (you can walk and can look after yourself) within the last 2 weeks. * patients who have at least one lesion that can be accurately assessed exclusion criteria: * patients who have recently received or are receiving prohibited medications or treatments * patients who have any unresolved side effects of previous treatments * patients who have spinal cord compression or brain metastases * patients who have severe systemic diseases (e.g., uncontrolled hypertension, hepatitis b, hepatitis c and human immunodeficiency virus \[hiv\] infection) * patients with significant abnormal ecg findings

Keywords: advanced solid malignancies malignant lymphoma
a phase 1 trial to assess safety, tolerability and pharmacokinetics of alia-1758 in healthy participants

Conditions: Alzheimer Disease

Summary: this is a phase 1, first in human (fih), double-blind, placebo-controlled, single ascending dose (sad) trial to assess the safety, tolerability, and pharmacokinetics (pk) of intravenously (iv) or subcutaneously (sc) injected alia-1758 in healthy male and female participants.


Eligibility criteria:
key inclusion criteria: * participants must understand the nature of the trial and must provide signed and dated written informed consent in accordance with local regulations before the conduct of any trial-related procedures. * healthy as determined by the investigator, based on a medical evaluation including medical history, physical examination, laboratory tests and electrocardiogram (ecg) recording. a participant with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if, in the opinion of the investigator, the finding is (a) unlikely to introduce additional risk to the participant, (b) will not interfere with trial procedures or confound trial results, and (c) is not otherwise exclusionary (see exclusion criteria). * body weight of at least 50.0 kg for men and 45.0 kg for women and body mass index (bmi) within the range of 17.5-32.0 kg/m2 (inclusive) at screening. key exclusion criteria: * a history or presence of a clinically significant hepatic, biliary, renal, gastrointestinal, cardiovascular, endocrine, pulmonary, ophthalmologic, immunologic, hematologic, dermatologic, psychiatric, neurologic abnormality, or chronic urinary tract infections. * a clinically significant abnormality on physical examination, ecg, or laboratory evaluations at screening or between screening and (first) dose administration. * the participant is, in the opinion of the investigator or medical monitor, unlikely to comply with the protocol or is unsuitable for any reason. other criteria may apply